Shomari Thompson
Family Medicine · Hattiesburg, MSNPI 1194286252
Payments from drug & device makers
Across 105 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$871
- Lilly USA, LLC$292
- Pfizer$240
- Boehringer Ingelheim$144
- Amgen$132
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$131
- plus $616 from 12 others
What the payments were for
- Food & beverage$2,428100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $871 |
| Lilly USA, LLC | 13 | $292 |
| Pfizer | 9 | $240 |
| Boehringer Ingelheim | 2 | $144 |
| Amgen | 8 | $132 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $131 |
| AstraZeneca | 1 | $106 |
| Sanofi | 1 | $98 |
| Novo Nordisk | 4 | $77 |
| GSK | 4 | $75 |
| Medtronic | 3 | $52 |
| Corcept Therapeutics | 2 | $44 |
| Insulet Corporation | 2 | $41 |
| Advanced Respiratory, Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Bayer | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,428 in reported general payments places this provider in the 70th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $76,642 |
| LinzessLinaclotide | 62 | $64,805 |
| JardianceEmpagliflozin | 63 | $62,415 |
| TrulicityDulaglutide | 19 | $28,602 |
| FarxigaDapagliflozin Propanediol | 23 | $27,538 |
| MounjaroTirzepatide | 24 | $26,663 |
| JanuviaSitagliptin Phosphate | 23 | $22,613 |
| EliquisApixaban | 28 | $20,754 |
| XareltoRivaroxaban | 18 | $16,550 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $16,473 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $13,286 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $11,117 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,105 |
| TrulancePlecanatide | 11 | $5,975 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $5,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $77 | $76,64266 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $144 | $73,53276 claims |
| AbbVieLinzess | $871 | $64,80562 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $292 | $55,26543 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $106 | $40,84661 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix | $75 | $32,92056 claims |
| PfizerEliquis | $240 | $20,75428 claims |
| Johnson & JohnsonXarelto | $18 | $16,55018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Hattiesburg
- Rambod RouhbakhshHattiesburg$6M
- Omolara OtaigbeHattiesburg$17K
- Deborah CopelandHattiesburg$13K
- J DumasHattiesburg$12K
- Anny EvansHattiesburg$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.